Leczenie niepłodności u kobiet z epilepsją: przegląd systematyczny
Infertility treatment in women with epilepsy: A systematic review
W skrócie
Badania pokazują, że zabiegi wspomagające rozrodczość (takie jak zapłodnienie in vitro) są bezpieczne dla kobiet z epilepsją i zazwyczaj nie pogorszają kontroli napadów. Głównym zagrożeniem jest zmiana stężenia leków przeciwpadaczkowych, szczególnie lamotrzyny, spowodowana hormonami stosowanymi w leczeniu niepłodności, co może prowadzić do przełamywania się napadów. Przeprowadzono przegląd czterech badań naukowych, w których kobiety z epilepsją otrzymywały różne leki przeciwpadaczkowe podczas prób zapłodnienia i wiele z nich osiągnęło udane ciąże.
Oryginalny abstract (angielski)
BACKGROUND: The impact of assisted reproductive technologies (ART) on seizure control in women with epilepsy remains incompletely understood. METHODS: A systematic review was conducted according to PRISMA guidelines. EMBASE, MEDLINE, CINAHL, Scopus, and the Cochrane Library were searched from inception to March 2025. Eligible studies included observational studies and case-based reports involving women undergoing infertility treatment. RESULTS: A total of 1216 publications were identified, of which four studies met the inclusion criteria, including case reports, a case series, and a cohort study. These studies included 16 women aged 25-46 years undergoing infertility treatment, all but one of whom had epilepsy. Interventions involved in vitro fertilization (IVF), ovulation induction, and hormonal therapies. Patients were treated with a range of antiseizure medications (ASMs), including carbamazepine, clobazam, lamotrigine, levetiracetam, oxcarbazepine, valproate, and zonisamide, either as monotherapy or in combination. Seizure frequency was generally stable, with most patients maintaining baseline seizure control. Seizure exacerbations were uncommon and primarily associated with hormonal therapy and reduced ASM levels, particularly reduced lamotrigine levels. Reported events included breakthrough seizures in the setting of decreased lamotrigine concentrations, seizure clusters associated with follitropin beta, and a new-onset seizure following dehydroepiandrosterone exposure. Across studies, multiple ART attempts resulted in live births with different ASM regimens, as well as in patients not receiving ASMs. CONCLUSION: Available evidence suggests that ART is feasible in women with epilepsy, with most patients maintaining stable seizure control. Hormonal therapy may affect ASM pharmacokinetics and seizure threshold, thereby warranting close monitoring. Larger prospective studies are needed to better define ASM-specific effects and optimize care.